

Serveur Académique Lausannois SERVAL [serval.unil.ch](https://serval.unil.ch)

## Author Manuscript

Faculty of Biology and Medicine Publication

**This paper has been peer-reviewed but does not include the final publisher proof-corrections or journal pagination.**

Published in final edited form as:

**Title:** Cardiovascular health and sleep disturbances in two population-based cohort studies.

**Authors:** Hausler N, Lisan Q, Van Sloten T, Haba-Rubio J, Perier MC, Thomas F, Danchin N, Guibout C, Boutouyrie P, Heinzer R, Jouven X, Marques-Vidal P, Empana JP

**Journal:** Heart (British Cardiac Society)

**Year:** 2019 Apr 8

**DOI:** 10.1136/heartjnl-2018-314485

In the absence of a copyright statement, users should assume that standard copyright protection applies, unless the article contains an explicit statement to the contrary. In case of doubt, contact the journal publisher to verify the copyright status of an article.

**Title:** Cardiovascular Health and Sleep Disturbances in two Population-based Cohort Studies

**Authors:** Nadine Häusler<sup>\*a</sup>, Quentin Lisan<sup>\*b,c,d</sup>, Thomas Van Sloten<sup>b,c,e</sup>, José Haba-Rubio<sup>f</sup>, Marie-Cécile Perier<sup>b,c</sup>, Frederique Thomas<sup>g</sup>, Nicolas Danchin<sup>b,g</sup>, Catherine Guibout<sup>b,c</sup>, Pierre Boutouyrie<sup>b,h,i</sup>, Raphaël Heinzer<sup>f</sup>, Xavier Jouven<sup>b,c,j</sup>, Pedro Marques-Vidal<sup>\*\*a</sup>, Jean-Philippe Empana<sup>\*\*b,c</sup>

\* NH and QL contributed equally to that study

\*\* PMV and JPE contributed equally to that study

### Affiliations

<sup>a</sup> Department of Medicine, Internal Medicine, Lausanne University Hospital (CHUV), Lausanne, Switzerland

<sup>b</sup> Paris Descartes University, Faculty of Medicine, Paris, France.

<sup>c</sup> INSERM, UMR-S970, Paris Cardiovascular Research Center, Department of Epidemiology, Paris, France.

<sup>d</sup> AP-HP, Georges Pompidou European Hospital, Department of Head and Neck surgery, Paris, France

<sup>e</sup> Cardiovascular Research Institute Maastricht and Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, the Netherlands

<sup>f</sup> Center for Investigation and Research in Sleep (CIRS), Lausanne University Hospital (CHUV), Lausanne, Switzerland

<sup>g</sup> Preventive and Clinical Investigation Center, Paris, France.

<sup>h</sup> INSERM, UMR-S970, Paris Cardiovascular Research Center, Department of Arterial Mechanics, Paris, France.

<sup>i</sup> AP-HP, Georges Pompidou European Hospital, Department of Pharmacology, Paris, France.

<sup>j</sup> AP-HP, Georges Pompidou European Hospital, Department of Cardiology, Paris, France

### Corresponding author

[Dr Jean-Philippe EMPANA](mailto:jean-philippe.empana@inserm.fr), INSERM U970, Paris Cardiovascular Research Center, Team 4, 56 Rue Leblanc, 75015 Paris, France, Phone: +33 1 53 98 80 20, Fax: +33 1 53 98 79 54, Email: [jean-philippe.empana@inserm.fr](mailto:jean-philippe.empana@inserm.fr)

Mis en forme : Anglais (États-Unis)

Mis en forme : Anglais (États-Unis)

**Word count:** 2983

**Abstract word count:** 241

## **Abstract**

**Objective:** We aimed to investigate the association between cardiovascular health (CVH), as defined by the American Heart Association, and several sleep disturbances.

**Methods:** Two community-based cohorts, the Paris Prospective Study 3 (PPS3, France, n=6,441) and the CoLaus study (Switzerland, n=2,989) were analyzed. CVH includes 7 metrics which all can be classified as poor, intermediate and ideal. Global CVH score was categorized into poor (0-2 ideal metrics), intermediate (3-4 ideal metrics) and ideal ( $\geq 5$  ideal metrics). Associations between global CVH and self-reported sleep disturbances [proxy of sleep-disordered breathing (SDB), excessive daytime sleepiness, insomnia symptoms and short/long sleep duration] and SDB severity measured by polysomnography (PSG) were investigated. Adjusted odds ratio (OR)/relative risk ratio (RRR) and 95% confidence intervals (CI) were estimated. Subjects with previous cardiovascular disease were excluded.

**Results:** Compared to poor CVH, subjects with intermediate and ideal global CVH had lower odds of self-reported SDB in both cohorts (ORs up to 0.55; 95% CI 0.44-0.68 and 0.35; 95% CI 0.22-0.53, respectively) and had lower SDB severity measured by PSG (RRR up to 0.07; 95% CI 0.02-0.20) in CoLaus. Subjects with intermediate and ideal global CVH had lower odds of excessive daytime sleepiness in PPS3 (ORs 0.82; 0.72-0.95 and 0.80; 0.82-1.02, respectively). No consistent associations were found between CVH and sleep duration or insomnia symptoms.

**Conclusions:** Higher levels of CVH are associated with lower odds of SDB and excessive daytime sleepiness. However, causal interpretation cannot be made and associations might be bidirectional.

## **Key questions**

### What is already known about this subject?

- Single cardiovascular risk factors are associated with sleep disturbances.
- Although cardiovascular risk factors usually cluster, their combined effect on sleep disturbances remains unknown.

### What does this study add?

- In two population-based cohort studies, higher cardiovascular health - a cluster of modifiable cardiovascular risk factors defined by the American Heart Association – was associated with lower odds of self-reported and objectively measured sleep disordered breathing (odd ratio up to 0.35; 95% confidence interval 0.22-0.53) and excessive daytime sleepiness (odd ratio up to 0.82; 95% confidence interval 0.72-0.95 ).

### How might this impact on clinical practice?

- Given the high prevalence of sleep disordered breathing and excessive daytime sleepiness in the population and their adverse health consequences, promoting higher cardiovascular health to prevent the development of risk factors associated with sleep disordered breathing and excessive daytime sleepiness has the potential for important public health implications.

## **Introduction**

The prevalence of sleep disturbances such as sleep-disordered breathing (SDB, 23% in women and 50% in men),<sup>1</sup> excessive daytime sleepiness (EDS, 20%),<sup>2</sup> insomnia (17%)<sup>3</sup> and short or long sleep durations (35%),<sup>4</sup> is increasing in the population.<sup>3,5</sup> These sleep disturbances have been linked to poor quality of life,<sup>6</sup> increased risk of dementia<sup>7</sup> and cardiovascular disease (CVD), and higher mortality.<sup>8-10</sup> Therefore, identifying modifiable risk factors for sleep disturbances is of public health relevance.

Single cardiovascular risk factors have been associated with several sleep disturbances.<sup>10,11</sup> However, most studies considered single cardiovascular risk factors, although they usually cluster and have an additive effect. The association between clustered cardiovascular risk factors and sleep disturbances remains unclear. Furthermore, most prior studies focused on associations between cardiovascular risk factors and a single sleep disturbance, precluding to help define whether a common or a specific sleep disturbance prevention strategy should be recommended.

The American Heart Association (AHA) has recently re-emphasized the concept of primordial prevention, *i.e.* the prevention of cardiovascular risk factors onset. Hence, the AHA developed the Life's Simple 7, a 7-items tool including four behavioral and three biological metrics to define poor, intermediate and ideal cardiovascular health (CVH).<sup>12</sup> The importance of CVH has been demonstrated by several population-based studies reporting substantial and graded risk reductions in mortality and incident CVD for subjects with intermediate and ideal CVH compared to those with poor CVH.<sup>13-16</sup> Given that sleep disturbances and CVD share some common risk factors, we hypothesized that higher CVH would be related to lower risk of sleep

disturbances. Therefore, using two large contemporary community-based European studies, we quantified the association of CVH with several sleep disturbances.

## **Methods**

### **Study population**

Details are described in the **supplementary methods**.

#### **The Paris Prospective Study 3**

The PPS3 (Paris, France) is a prospective observational population-based cohort study on novel determinants of the main phenotypes of CVD.<sup>17</sup> Between 2008 and 2012 10,157 men and women aged 50-75 years were recruited in a preventive medical center. The study-protocol was approved by the Ethics Committee of the Cochin Hospital (Paris, France) and all volunteers signed an informed consent form. The standard health check-up included a complete clinical examination including measurement of height, weight and blood pressure, coupled with standard biological tests after an overnight fast. A self-administered questionnaire provided information related to sleep habits, lifestyle (tobacco and alcohol consumption, physical activity, diet), personal and family medical history and current health status.

#### **The CoLaus Study**

This is a Swiss population-based observational prospective study investigating determinants of cardiovascular disease.<sup>18</sup> Between 2003 and 2006, 6,733 subjects (age range 35-75 years) were included from a random sample of the population of Lausanne, Switzerland. The institutional Ethics Committee of the University of Lausanne approved the study (references

16/03 and 33/09) and all participants gave their signed informed consent. The first follow-up of the cohort (median follow-up time 5.4 years) included 5,064 subjects. Subjects underwent a physical examination after an overnight fasting and responded to a questionnaire covering demographic and medical history, health behaviors and sleep quality measures.

### **Cardiovascular Health**

The AHA criteria were used to define the level of each metric and *global CVH* was categorized as poor, intermediate and ideal to reflect 0-2, 3-4 and 5-7 metrics at ideal.<sup>12</sup> Similarly, *behavioral CVH* (smoking, body mass index, diet and physical activity) was categorized as poor, intermediate and ideal to reflect 0-1, 2 and 3-4 behavioral metrics at the ideal level; *biological CVH* (hypertension, total cholesterol and fasting blood glucose) was categorized as poor, intermediate and ideal to reflect to 0-1, 2 and 3 metrics at the ideal level (**supplementary methods** and **supplementary table 1**).<sup>12</sup>

In sensitivity analysis (see below), *global CVH* was examined as a continuous variable considering i) the number of metrics at ideal level (from 0 to 7) and ii) a global cardiovascular health score, calculated by assigning 0 point for each metric at poor level, 1 point for metric at intermediate level and 2 points for metric at ideal level (ranging from 0 to 14).<sup>12</sup>

### **Sleep quality measures**

#### Sleep-disordered breathing

In both cohorts, a proxy including the main risk factors for SDB was used to measure SDB.<sup>19</sup> Participants reporting to snore at least 1-2 times per week (in CoLaus) or to snore

regularly or often (in PPS3) and being male and/or being at least 55 years old and/or having a BMI  $\geq 30$  kg/m<sup>2</sup> and/or having hypertension and/or having EDS were considered to have SDB (**supplementary table 2**).

In CoLaus, a subset of the study population underwent polysomnography.<sup>1</sup> SDB was objectively measured, calculated as the average number of apnea/hypopnea per hours of sleep (apnea-hypopnea index, AHI), and categorized as normal (AHI 0-4), mild (AHI 5-14), moderate (AHI 15-29) and severe (AHI  $\geq 30$ ) according to the American Academy of Sleep Medicine.<sup>20</sup>

#### Excessive daytime sleepiness

Excessive daytime sleepiness (EDS) was assessed using the Epworth Sleepiness Scale (ESS) in both cohorts.<sup>21</sup> EDS was defined by an ESS  $\geq 11$ .<sup>21</sup>

#### Sleep duration

In both cohorts, sleep duration was extracted from the Pittsburgh Sleep Quality Index.<sup>22</sup> Subjects reported their average hours of sleep per night during the last month. Sleep duration was categorized into short ( $\leq 6$  hours/night), normal (6-9 hours/night), and long ( $\geq 9$  hours/night).

#### Insomnia symptoms

Insomnia symptoms were measured using questions from the Pittsburgh Sleep Quality Index. Insomnia symptoms were considered present (yes/no) when subjects reported difficulties initiating sleep and difficulties maintaining sleep or early morning awakening 3-4 times per week.



## **Confounders**

In PPS3, depression score was assessed using the 13-item Questionnaire of Depression second version, Abridged.<sup>23</sup> Depressive status (yes/no) was defined by a score  $\geq 7$ . In CoLaus, depressive status was measured with the validated 20-item Center for Epidemiologic Studies – Depression Scale questionnaire, and depressive status was considered for a score  $\geq 17$  for men and 23 for women.<sup>24</sup> Education level was categorized as low (no graduation in PPS3, mandatory education or apprenticeship in CoLaus), intermediate (high school diploma) and high (university diploma). We categorized alcohol consumption as never/less than daily, 1-2 glasses per day and  $\geq 3$  glasses per day. A medical doctor checked the use of medications during a face-to-face interview in PPS3. In CoLaus, subjects self-reported the use of prescribed and over the counter medications.

## **Exclusion criteria**

Participants were excluded from the analyses if they had i) previous history of CVD; ii) missing data on more than one CVH metric; iii) missing data on any sleep variables or iv) missing data on any covariates.

## **Statistical analyses**

Statistical analyses were performed using R version 3.3.3 for PPS3 ([www.r-project.org](http://www.r-project.org)) and STATA 15.1 for CoLaus (Stata Corp, College Station, TX, USA).

### Single cohort analyses

The association between global CVH (main exposure) and binary sleep disturbances (outcomes), *i.e.* proxy for SDB, EDS and insomnia symptoms, were examined by logistic regressions for each cohort and prevalence ratios [to be considered as an odds-ratio (OR)] were obtained. The association between CVH and SDB measured by PSG (four categories) and sleep duration (three categories, with 6-9 hours/night as the reference) was quantified by multinomial logistic regressions and relative risk ratios (RRR) were estimated. Regression models adjusted for age, sex, education, living alone status, depression, use of sleep medications and alcohol consumption. Further, the same analyses were performed using behavioral and biological CVH as independent variables (secondary exposure).

Mis en forme : Anglais (États-Unis)

### Pooled data cohort analyses

Mixed effects regressions models with random effects for the cohort were used. Logistic mixed models were used for binary outcomes (proxy for SDB, EDS and insomnia symptoms), whereas linear mixed models were used for sleep duration considered here as a continuous outcome (the normality distribution of the model's residuals was graphically checked). Pooled data analyses were adjusted for the same covariates as for the single cohort analysis. As for the single cohort analysis, global CVH but also behavioral and biological CVH were examined.

Mis en forme : Anglais (États-Unis)

Mis en forme : Anglais (États-Unis)

### Sensitivity analyses

First, subjects with missing data on any CVH metrics were excluded. Second, the adapted CVH metric diet was measured by all available metrics in each cohort (additionally including sodium in PPS3 and fiber in CoLaus) and time since smoking cessation was taken into account

for the smoking status in PPS3. Third, the association between CVH and each sleep disturbance was further mutually adjusted for the other three sleep disturbances. Fourth, CVH was measured as a continuous variable considering either the number of metrics at the ideal level (0 to 7) or the cardiovascular health score as defined above (ranging from 0 to 14). Next, to limit collinearity, BMI and hypertension were excluded from the definition of CVH and sex was not adjusted for, when estimating its related odds for a proxy for SDB (containing BMI, hypertension and sex in its definition). In this sensitivity analysis, poor, intermediate and ideal CVH corresponded to 0-2, 3, 4-5 metrics at ideal level. Last, we assessed the relationship between global CVH and sleep duration measured by polysomnography in CoLaus.

## **Results**

### **Study population**

From 8,583 participants in PPS3 who answered the sleep questionnaires and from the 5,064 subjects participating in follow-up 1 in CoLaus, respectively 6,441 and 2,989 participants were free of previous CVD and had full data (**figure 1**). Out of the 2,989 subjects in CoLaus, 1,404 had PSG data. The characteristics of excluded and included participants are compared in **supplementary table 3**.

### **Prevalence of sleep disturbances and bivariate association with CVH**

As presented in **table 1**, ideal CVH was present in 9.5% (PPS3) and 11.2% (CoLaus) of the participants. In both cohorts, participants with ideal CVH were more frequently women, had a higher educational level, were more frequently living alone and drank less alcohol. Proxy for

SDB was present in 33% (PPS3) and 20% (CoLaus) of the participants, and decreased with an increasing level of global CVH in both cohorts (p-value<0.001). In CoLaus, prevalence of moderate/severe SDB measured by PSG was 35% and decreased with an increasing level of global CVH (p-value<0.001). EDS was present in 17% (PPS3) and 11% (CoLaus) of the participants, and decreased with increasing level of global CVH in PPS3 (p-value=0.02) but not in CoLaus (p-value=0.41). Insomnia symptoms were present in 14.4% (PPS3) and 7% (CoLaus) of the participants, and decreased with increasing level of global CVH in CoLaus (p-value=0.07) but not in PPS3 (p-value=0.18). There were 25% and 8% of the participants sleeping 6 hours or less per night in PPS3 and CoLaus respectively; and 5,1% and 1.3% sleeping 9 hours or more per night in each cohort. There was no clear pattern between the distribution of short/long sleep duration and global CVH level.

#### **Association of CVH and sleep disturbances: single cohort analysis**

##### CVH and SDB

As presented in **figure 2**, in multivariable logistic regression analysis, the odds for proxy for SDB gradually decreased in subjects with intermediate and ideal levels of global CVH compared to subjects with poor CVH in both cohorts (p-value<0.001 in both cohorts). There was a stronger inverse gradient between higher global CVH and the severity of SDB measured by PSG in a subsample of CoLaus (p-value<0.001, **table 2**).

These inverse associations with either the proxy for SDB (**figure 2**) or SDB measured by PSG in the subsample of CoLaus (**table 2**), were observed for the behavioral and biological CVH.

### CVH and EDS

In PPS3, subjects with intermediate and ideal global CVH had lower odds of EDS compared to subjects with poor CVH while no association was found in CoLaus (**figure 2**).

In both cohorts, subjects with intermediate and ideal levels of behavioral CVH had lower odds of EDS, when compared to subjects with poor CVH, although the association with ideal behavioral CVH was borderline significant in CoLaus ( $p=0.08$ ). Conversely, in both cohorts, subjects with higher biological CVH had higher odds of EDS; however these associations were statistically significant only for subjects with ideal compared to poor biological CVH in CoLaus.

### CVH, insomnia symptoms and sleep duration

In both cohorts, no consistent associations were found between CVH and both and insomnia symptoms and sleep duration (**supplementary table 4**).

### **Pooled analysis**

Results of the pooled analysis are reported in **table 3**. The odds for SDB remained significant, being 0.62 (95% CI 0.56 – 0.68) and 0.41 (95% CI 0.33 – 0.49) for intermediate and ideal global CVH when compared to poor global CVH, respectively. The odds for EDS became significant, being 0.87 (95% CI 0.77 – 0.99) and 0.80 (95% CI 0.65 – 0.98) for intermediate and ideal global CVH, respectively. As for the single cohort analysis, there was no significant association between intermediate and ideal global CVH and insomnia or sleep duration.

### **Sensitivity analyses**

Effect size and direction of the association between global CVH and sleep disturbances were consistent with those obtained in main analyses in both cohorts (**supplementary table 5 and supplementary figure 1**).

### **Discussion**

In two large European population-based studies, higher global, behavioral and biological CVH were consistently associated with lower odds of SDB, and higher behavioral CVH was related to lower odds of EDS compared to subjects with poor CVH. In addition, there was some evidence for an association between higher levels of CVH and lower odds for short/long sleep duration. Conversely, CVH was not related to insomnia symptoms.

The distribution of ideal CVH was in the same range in PPS3 (9.5%) and CoLaus (11.2%). In addition, the distribution of socio-demographic characteristics across the levels of CVH was exactly the same in both cohorts. However, there was some difference in the distribution of sleep disturbances between the two studies, in particular regarding the proxy for SDB or short and long sleep duration, although sleep disturbances definitions have been harmonized as much as possible. Notwithstanding these differences, associations between CVH and sleep disturbances were consistent in PPS3 and CoLaus, reinforcing the robustness of the findings.

### **CVH and SDB**

Although several cross-sectional studies have related single cardiovascular risk factors with SDB,<sup>1,25</sup> none investigated the combined association of cardiovascular risk factors as measured by CVH and SDB. In both PPS3 and CoLaus, the combination of several risk factors at intermediate or ideal compared to poor levels was associated with a reduced likelihood of having the proxy for SDB (up to 45% and 65% respectively). The gradual relationships between CVH and SDB were even stronger when the severity of SDB was objectively evaluated using PSG in CoLaus. Thus, the proxy for SDB is a rather conservative measure for SDB and accordingly, it underestimated the prevalence of SDB in CoLaus by 15% when compared to SDB measured by PSG. Finally, these evidences were found for both the behavioral and biological CVH. All these aspects emphasize the validity of the reported association between CVH and SDB. In addition, SDB has been shown to be a contributor to the onset of some of the CVH metrics such as diabetes, dyslipidemia, hypertension,<sup>10</sup> and obesity.<sup>26</sup> It is therefore likely that the association between CVH and SDB is bidirectional.

### **CVH and EDS**

Only one small (n=635) population-based study in rural Ecuador explored the potential relationship between global CVH and EDS and did not find any significant association.<sup>11</sup> Conversely, in our study, using a much larger sample size, two independent European cohorts and additionally considering the behavioral and the biological components of CVH, higher behavioral CVH in both cohorts were significantly associated with lower odds of EDS. This result is in line with previous studies that associated the presence of single cardiovascular risk factors belonging to behavioral CVH (*i.e.* obesity) with EDS.<sup>27</sup> However, the association

between ideal biological CVH and higher prevalence of EDS in both cohorts was unexpected although not confirmed in the pooled analysis, and additional studies are required to clarify this finding.

### **CVH and insomnia symptoms**

The lack of consistent association between CVH and insomnia symptoms in each study is in line with previous studies reporting no significant relationship between single behavioral cardiovascular risk factors – such as obesity, physical activity or smoking – and insomnia symptoms.<sup>28</sup> The present study further suggests the absence of additive effect of seven cardiovascular risk factors on insomnia symptoms.

### **CVH and sleep duration**

There was little evidence for an association between CVH and sleep duration. The relationship was neither gradual nor consistent between the two cohorts, and sensitivity analyses with objectively measured sleep duration did not indicate an association either.

### **Implications**

The lower odds of SDB and EDS associated with CVH carry important public health implications owing to the burden of sleep disturbances in the population and the wide range of sleep-related health consequences.<sup>6–10</sup> Importantly, the lower odds for both SDB and EDS were primarily driven by modifiable behavioral CVH that do not require pharmacological interventions. The results of our sensitivity analysis on CVH score suggest that gaining one additional metric at ideal level is already associated with significant reduced odds of SDB and, to



a lesser extent, EDS. Hence, this approach might be more achievable than promoting to the population the attainment of an ideal global CVH to help preventing the onset of SDB and EDS.

### **Study limitations**

First, as a cross-sectional analysis, causal interpretation cannot be made and associations might be bidirectional. Second, both cohorts are based on voluntary participation resulting in a possible overrepresentation of health aware subjects. Third, sleep disturbances, some cardiovascular risk factors and covariates were self-reported and thus prone to recall, misclassification and reporting bias. Fourth, the 7-item tool used to assess CVH assigns the same weights to each of the metric and further studies are required to refine the tool. Fifth, there were a few participants ( $n < 30$ ) by CVH group in some analyses of sleep disturbances, which may have contributed to the lack of statistical significance and wide confidence intervals. Sixth, declustering the Life's Simple 7 into behavioral and biological CVH is likely to lower the statistical power of these sub-analyses explaining why both subscales were considered as secondary exposures.

### **Conclusions**

Higher levels of CVH were associated with lower odds of SDB and EDS. In addition to benefit on mortality and cardiovascular disease risk, the current study suggests that higher CVH may have secondary benefit on highly prevalent sleep disturbances. Longitudinal and intervention studies are needed to support the promotion of CVH to prevent the development of risk factors associated with SDB and EDS.

Mis en forme : Anglais (États-Unis)

### **Statements**

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive license on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article (if accepted) to be published in HEART editions and any other BMJPGGL products to exploit all subsidiary rights

### **Funding**

- The PPS3 Study was supported by grants from The National Research Agency (ANR), the Research Foundation for Hypertension (RFHTA), the Research Institute in Public Health (IRESP) and the Region Ile de France (Domaine d'Intérêt Majeur).

- The CoLaus study was and is supported by research grants from GlaxoSmithKline, the Faculty of Biology and Medicine of Lausanne, and the Swiss National Science Foundation (grants 33CSCO-122661, 33CS30-139468, 33CS30-148401 and grant 320030E-176280).

**Competing interests:** None declared.

## **References**

1. Heinzer R, Vat S, Marques-Vidal P, Marti-Soler H, Andries D, Tobback N, Mooser V, Preisig M, Malhotra A, Waeber G, Vollenweider P, Tafti M, Haba-Rubio J. Prevalence of sleep-disordered breathing in the general population: the HypnoLaus study. *Lancet Respir Med*. 2015;3:310–318.
2. Whitney CW, Enright PL, Newman AB, Bonekat W, Foley D, Quan SF. Correlates of daytime sleepiness in 4578 elderly persons: the Cardiovascular Health Study. *Sleep*. 1998;21:27–36.
3. Garland SN, Rowe H, Repa LM, Fowler K, Zhou ES, Grandner MA. A decade's difference: 10-year change in insomnia symptom prevalence in Canada depends on sociodemographics and health status. *Sleep Health*. 2018;4:160–165.
4. Liu Y, Wheaton AG, Chapman DP, Cunningham TJ, Lu H, Croft JB. Prevalence of Healthy Sleep Duration among Adults--United States, 2014. *MMWR Morb Mortal Wkly Rep*. 2016;65:137–141.
5. Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased prevalence of sleep-disordered breathing in adults. *Am J Epidemiol*. 2013;177:1006–1014.
6. Baldwin CM, Griffith KA, Nieto FJ, O'Connor GT, Walsleben JA, Redline S. The association of sleep-disordered breathing and sleep symptoms with quality of life in the Sleep Heart Health Study. *Sleep*. 2001;24:96–105.
7. Hung C-M, Li Y-C, Chen H-J, Lu K, Liang C-L, Liliang P-C, Tsai Y-D, Wang K-W. Risk of dementia in patients with primary insomnia: a nationwide population-based case-control study. *BMC Psychiatry*. 2018;18:38.
8. He Q, Zhang P, Li G, Dai H, Shi J. The association between insomnia symptoms and risk of cardio-cerebral vascular events: A meta-analysis of prospective cohort studies. *Eur J Prev Cardiol*. 2017;24:1071–1082.
9. Empana J-P, Dauvilliers Y, Dartigues J-F, Ritchie K, Garipey J, Jouven X, Tzourio C, Amouyel P, Besset A, Ducimetiere P. Excessive daytime sleepiness is an independent risk indicator for cardiovascular mortality in community-dwelling elderly: the three city study. *Stroke J Cereb Circ*. 2009;40:1219–1224.

10. Grandner MA, Alfonso-Miller P, Fernandez-Mendoza J, Shetty S, Shenoy S, Combs D. Sleep: important considerations for the prevention of cardiovascular disease. *Curr Opin Cardiol.* 2016;31:551–565.

Mis en forme : Italien (Italie)

11. Del Brutto OH, Mera RM, Zambrano M, Castillo PR. Excessive daytime somnolence and cardiovascular health: A population-based study in rural Ecuador. *Sleep Sci São Paulo Braz.* 2014;7:186–188.

12. Lloyd-Jones DM, Hong Y, Labarthe D, Mozaffarian D, Appel LJ, Van Horn L, Greenlund K, Daniels S, Nichol G, Tomaselli GF, Arnett DK, Fonarow GC, Ho PM, Lauer MS, Masoudi FA, Robertson RM, Roger V, Schwamm LH, Sorlie P, Yancy CW, Rosamond WD, American Heart Association Strategic Planning Task Force and Statistics Committee. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond. *Circulation.* 2010;121:586–613.

13. Yang Q, Cogswell ME, Flanders WD, Hong Y, Zhang Z, Loustalot F, Gillespie C, Merritt R, Hu FB. Trends in cardiovascular health metrics and associations with all-cause and CVD mortality among US adults. *JAMA.* 2012;307:1273–1283.

14. Folsom AR, Yatsuya H, Nettleton JA, Lutsey PL, Cushman M, Rosamond WD, ARIC Study Investigators. Community prevalence of ideal cardiovascular health, by the American Heart Association definition, and relationship with cardiovascular disease incidence. *J Am Coll Cardiol.* 2011;57:1690–1696.

15. Gaye B, Canonico M, Perier M-C, Samieri C, Berr C, Dartigues J-F, Tzourio C, Elbaz A, Empana J-P. Ideal Cardiovascular Health, Mortality, and Vascular Events in Elderly Subjects: The Three-City Study. *J Am Coll Cardiol.* 2017;69:3015–3026.

16. Samieri C, Perier M-C, Gaye B, Proust-Lima C, Helmer C, Dartigues J-F, Berr C, Tzourio C, Empana J-P. Association of Cardiovascular Health Level in Older Age With Cognitive Decline and Incident Dementia. *JAMA.* 2018;320:657–664.

17. Empana J-P, Bean K, Guibout C, Thomas F, Bingham A, Pannier B, Boutouyrie P, Jouven X, PPS3 Study Group. Paris Prospective Study III: a study of novel heart rate parameters, baroreflex sensitivity and risk of sudden death. *Eur J Epidemiol.* 2011;26:887–892.

18. Firmann M, Mayor V, Vidal PM, Bochud M, Pécoud A, Hayoz D, Paccaud F, Preisig M, Song KS, Yuan X, Danoff TM, Stirnadel HA, Waterworth D, Mooser V, Waeber G, Vollenweider P. The CoLaus study: a population-based study to investigate the epidemiology

and genetic determinants of cardiovascular risk factors and metabolic syndrome. *BMC Cardiovasc Disord.* 2008;8:6.

19. Lisan Q, Tafflet M, Charles M-A, Thomas F, Boutouyrie P, Guibout C, Haba-Rubio J, Périer MC, Pannier B, Marques-Vidal P, Jouven X, Empana J-P. Self-reported body silhouette trajectories across the lifespan and excessive daytime sleepiness in adulthood: a retrospective analysis. The Paris Prospective Study III. *BMJ Open.* 2018;8:e020851.
20. Berry RB, Budhiraja R, Gottlieb DJ, Gozal D, Iber C, Kapur VK, Marcus CL, Mehra R, Parthasarathy S, Quan SF, Redline S, Strohl KP, Davidson Ward SL, Tangredi MM, American Academy of Sleep Medicine. Rules for scoring respiratory events in sleep: update of the 2007 AASM Manual for the Scoring of Sleep and Associated Events. Deliberations of the Sleep Apnea Definitions Task Force of the American Academy of Sleep Medicine. *J Clin Sleep Med.* 2012;8:597–619.
21. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. *Sleep.* 1991;14:540–545.
22. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. *Psychiatry Res.* 1989;28:193–213.
23. Pichot P. A self-report inventory on depressive symptomatology (QD2) and its abridged form (QD2). In *Assessment of Depression.* Springer. 1986;108–22.
24. Fuhrer R, Rouillon F. The French version of the CES-D (Center for Epidemiologic Studies-Depression Scale). *Eur Psychiatry.* 1989;4:163–166.
25. Shahar E, Whitney CW, Redline S, Lee ET, Newman AB, Nieto FJ, O'Connor GT, Boland LL, Schwartz JE, Samet JM. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. *Am J Respir Crit Care Med.* 2001;163:19–25.
26. Brown MA, Goodwin JL, Silva GE, Behari A, Newman AB, Punjabi NM, Resnick HE, Robbins JA, Quan SF. The Impact of Sleep-Disordered Breathing on Body Mass Index (BMI): The Sleep Heart Health Study (SHHS). *Southwest J Pulm Crit Care.* 2011;3:159–168.
27. Bixler EO, Vgontzas AN, Lin H-M, Calhoun SL, Vela-Bueno A, Kales A. Excessive daytime sleepiness in a general population sample: the role of sleep apnea, age, obesity, diabetes, and depression. *J Clin Endocrinol Metab.* 2005;90:4510–4515.


28. LeBlanc M, Mérette C, Savard J, Ivers H, Baillargeon L, Morin CM. Incidence and risk factors of insomnia in a population-based sample. *Sleep*. 2009;32:1027–1037.

**Figure legends**

Figure 1: Selection procedure, Paris Prospective Study 3 (France) and CoLaus (Switzerland).

*Note*: numbers are for Paris Prospective Study 3/CoLaus.


*Abbreviations*: CVD: cardiovascular disease; CVH: cardiovascular health.



**Figure 2:** Association of global, behavioral and biological cardiovascular health with sleep disordered breathing and excessive daytime sleepiness, Paris Prospective Study 3 (France) and CoLaus (Switzerland).

*Note:* multivariable analysis conducted using logistic regression; results are expressed as odds ratio and 95% confidence interval.

*Abbreviations:* CVH: cardiovascular health, OR: odds ratio, CI: confidence interval.







**Table 1:** Characteristics of the study participants according to cardiovascular health status, Paris Prospective Study 3 (France, n=6,441) and CoLaus (Switzerland, n=2,989).

	Cardiovascular health			p-value
	Poor	Intermediate	Ideal	
<b>PPS3</b>	<b>N=3,007 (46.7)</b>	<b>N=2,820 (43.8)</b>	<b>N=614 (9.5)</b>	
<b>Sleep complaints</b>				
Sleep disordered breathing (proxy)	1,206 (40.1)	780 (27.7)	117 (19.1)	<0.001
Excessive daytime sleepiness	547 (18.2)	440 (15.6)	94 (15.3)	0.02
Insomnia symptoms	411 (13.7)	422 (15.0)	99 (16.1)	0.18
Sleep duration (hours per night)				0.27
≤6	845 (28.1)	773 (27.4)	162 (26.4)	
6-9	1,990 (66.2)	1,917 (68.0)	422 (68.2)	
≥9	172 (6.7)	130 (4.6)	30 (4.9)	
<b>General characteristics</b>				
Male gender	2,244 (74.6)	1,600 (56.7)	271 (44.1)	<0.001
Age (years)	59.3 ± 6.02	59.3 ± 6.21	59.2 ± 6.13	0.84
Education level				0.01
Low	851 (28.3)	704 (25.0)	152 (24.8)	
Intermediate	566 (18.8)	517 (18.3)	103 (16.8)	
High	1,590 (52.9)	1,599 (56.7)	359 (58.4)	
Living alone	598 (19.9)	672 (23.8)	158 (25.7)	<0.001
Alcohol (drinks per day)				<0.001
Never	469 (8.2)	314 (11.1)	98 (16.0)	
1-2	2,229 (74.1)	2,246 (79.6)	485 (79.0)	
≥3	532 (17.7)	260 (19.2)	31 (5.1)	

Depressive status	232 (7.7)	211 (7.5)	40 (6.5)	0.59
Sleep medications	275 (9.1)	296 (10.5)	64 (10.4)	0.20
<b>CoLaus</b>	<b>N=1,383 (46.3) N=1,272 (42.5) N=334 (11.2)</b>			
<b>Sleep complaints</b>				
Sleep disordered breathing (proxy)	392 (28.3)	176 (13.8)	27 (8.1)	<0.001
Severity of OSA (from PSG data)				
No	94 (14.7)	225 (37.4)	97 (58.8)	<0.001
Mild	230 (36.1)	227 (37.8)	45 (27.3)	
Moderate	171 (26.8)	96 (16)	19 (11.5)	
Severe	143 (22.4)	53 (8.8)	4 (2.4)	
Excessive daytime sleepiness	142 (10.3)	150 (11.8)	34 (10.2)	0.41
Insomnia symptoms	110 (8.0)	80 (6.3)	16 (4.8)	0.07
Sleep duration (hours per night)				
≤6	124 (9.0)	97 (7.6)	18 (5.4)	0.08
6-9	1,236 (89.4)	1,163 (91.4)	313 (93.7)	
≥9	23 (1.7)	12 (0.9)	3 (0.9)	
<b>General characteristics</b>				
Male gender	881 (63.7)	502 (39.5)	104 (31.1)	<0.001
Age (years)	59.0 ± 9.8	55.0 ± 9.7	50.8 ± 8.3	<0.001
Education				
Low	744 (53.8)	538 (42.3)	128 (38.3)	<0.001
Intermediate	363 (26.2)	380 (29.9)	82 (24.6)	
High	276 (20.0)	354 (27.8)	124 (37.1)	
Living alone	515 (37.2)	576 (45.3)	139 (41.6)	<0.001
Alcohol (drinks per day)				<0.001

Never	226 (16.3)	290 (22.8)	100 (29.9)	
1-2	1,107 (80.0)	964 (75.8)	233 (69.8)	
≥3	50 (3.6)	18 (1.4)	1 (0.3)	
Depressive status	175 (12.7)	158 (12.4)	34 (10.2)	0.46
Sleep medications	186 (13.5)	140 (11.0)	36 (10.8)	0.11

*Note:* numbers are N (%) or mean ± standard deviation. P-values are from Pearson chi-square or ANOVA where appropriate and refer to the global comparison across the 3 groups.

*Abbreviations:* OSA: obstructive sleep apnea; PSG: polysomnography.

**Table 2:** Results of multinomial logistic regression between severity of sleep disordered breathing as measured by polysomnography and global, behavioral and biological cardiovascular health in CoLaus (Switzerland, N=1,404).

	Severity of SDB (no = ref)		
	Mild	Moderate	Severe
	RRR (95% CI)	RRR (95% CI)	RRR (95% CI)
<b>Global CVH</b>			
Poor	1	1	1
Intermediate	0.52 (0.38 - 0.72)	0.37 (0.25 - 0.53)	0.29 (0.19 - 0.46)
Ideal	0.27 (0.17 - 0.42)	0.20 (0.11 - 0.36)	0.07 (0.02 - 0.20)
<b>Behavioral CVH</b>			
Poor	1	1	1
Intermediate	0.59 (0.42 - 0.81)	0.43 (0.29 - 0.62)	0.38 (0.25 - 0.58)
Ideal	0.39 (0.27 - 0.57)	0.22 (0.14 - 0.37)	0.17 (0.09 - 0.31)
<b>Biological CVH</b>			
Poor	1	1	1
Intermediate	0.64 (0.46 - 0.87)	0.51 (0.34 - 0.77)	0.33 (0.19 - 0.57)
Ideal	0.27 (0.15 - 0.49)	0.30 (0.14 - 0.65)	0.13 (0.03 - 0.58)

*Abbreviations:* SDB: sleep-disordered breathing; RRR: relative risk ratio; ref: reference category. *Note:* Models were adjusted for age, sex, education, living alone status, depression, use of sleep medications and alcohol consumption.

**Table 3:** Results of mixed effect regressions for the pooled analysis.

	SDB	EDS	Insomnia	Sleep duration
	OR (95% CI)	OR (95% CI)	OR (95% CI)	Regression coefficient (95% CI)
<b>Global CVH</b>				
Poor	1 (reference)	1 (reference)	1 (reference)	1 (reference)
Intermediate	0.62 (0.56 – 0.68)	0.87 (0.77 – 0.99)	0.89 (0.77 – 1.02)	-0.02 (-0.03 – 0.06)
Ideal	0.41 (0.33 – 0.49)	0.80 (0.65 – 0.98)	0.84 (0.67 – 1.06)	0.08 (-0.01 – 0.16)
<b>Behavioral CVH</b>				
Poor	1 (reference)	1 (reference)	1 (reference)	1 (reference)
Intermediate	0.66 (0.59 – 0.73)	0.76 (0.67 – 0.87)	1.01 (0.87 – 1.18)	-0.003 (-0.05 – 0.05)
Ideal	0.41 (0.36 – 0.47)	0.72 (0.61 – 0.85)	0.93 (0.78 – 1.11)	0.06 (0.001 – 0.13)
<b>Biological CVH</b>				
Poor	1 (reference)	1 (reference)	1 (reference)	1 (reference)
Intermediate	0.82 (0.72 – 0.92)	1.13 (0.98 – 1.30)	0.99 (0.84 – 1.16)	0.03 (-0.02 – 0.09)
Ideal	0.62 (0.48 – 0.80)	1.21 (0.93 – 1.56)	0.64 (0.44 – 0.92)	-0.03 (-0.14 – 0.08)

*Abbreviations:* CVH: cardiovascular health; SDB: sleep disordered breathing; EDS: excessive daytime sleepiness; OR: odd ratio; CI: confidence interval.

*Note:* odds ratios and regression coefficient were estimated by logistic and linear mixed effect regressions adjusted for age, sex, education, living alone status, depression, use of sleep medications and alcohol consumption.